Please upgrade your browser.
Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment
Why rely on the possibly unreliable interpretation of this important information by laymen when you can review the complete list of abstracts from the world's largest oncology meeting yourself? Become an empowered patient. Do your own research to develop an informed opinion.
Bizde Böbrek Kanseri var. Hastalar ve aileleri için pratik bir rehber.
Despite faring better, women need more blood than men.
Demonstrates Ability to Accurately Identify Tumor Tissue Origin in Patients With Cancer of Unknown and Uncertain Primary
A new study in the current issue of Pediatrics reveals that folic acid fortification of foods could potentially reduce the number of incidences of Wilm's tumor, the most common type of kidney cancer.
Pfizer, Inc. (PFE) said the Committee for Human Medicinal Products, or CHMP, of the European Medicines Agency has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union for the treatment of adult patients with advanced renal cell carcinoma.
"Spent the afternoon with two families dealing with kidney cancer. I lost my mom to this disease.. my dad & I were moved by their journey."
An investigational drug targeting all three forms of the vascular endothelial growth factor (VEGF) receptor was more effective against advanced renal cell carcinoma than a current standard agent, researchers found.
If this marker would be clinically validated, the marker could be used to distinguish patients that would benefit from the drug from those that would not, and spare them a futile therapy with possible side effects.
|Powered by NeonCRM|